235 related articles for article (PubMed ID: 37257847)
1. Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
Chandrakumaran P; Hews-Girard J; Poon MC
Haemophilia; 2023 Jul; 29(4):1095-1103. PubMed ID: 37257847
[TBL] [Abstract][Full Text] [Related]
2. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
4. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.
Nitu-Whalley IC; Griffioen A; Harrington C; Lee CA
Am J Hematol; 2001 Apr; 66(4):280-4. PubMed ID: 11279640
[TBL] [Abstract][Full Text] [Related]
5. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Federici AB
Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
[TBL] [Abstract][Full Text] [Related]
6. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
[TBL] [Abstract][Full Text] [Related]
7. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease.
Revel-Vilk S; Schmugge M; Carcao MD; Blanchette P; Rand ML; Blanchette VS
J Pediatr Hematol Oncol; 2003 Nov; 25(11):874-9. PubMed ID: 14608197
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
9. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.
Castaman G; Lattuada A; Mannucci PM; Rodeghiero F
Br J Haematol; 1995 Jan; 89(1):147-51. PubMed ID: 7833254
[TBL] [Abstract][Full Text] [Related]
10. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history.
Sánchez-Luceros A; Meschengieser SS; Woods AI; Chuit R; Turdó K; Blanco A; Lazzari MA
Thromb Haemost; 2010 Nov; 104(5):984-9. PubMed ID: 20886181
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and management of von Willebrand disease].
Higasa S; Tokugawa T; Sawada A
Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
[TBL] [Abstract][Full Text] [Related]
13. Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra-platelet von Willebrand factor.
Rodeghiero F; Castaman G; Di Bona E; Ruggeri M; Lombardi R; Mannucci PM
Eur J Haematol; 1988 Feb; 40(2):163-7. PubMed ID: 3126081
[TBL] [Abstract][Full Text] [Related]
14. A personalized approach to the management of VWD.
Phua CW; Berntorp E
Transfus Apher Sci; 2019 Oct; 58(5):590-595. PubMed ID: 31466808
[TBL] [Abstract][Full Text] [Related]
15. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
Federici AB; Bucciarelli P; Castaman G; Baronciani L; Canciani MT; Mazzucconi MG; Morfini M; Rocino A; Schiavoni M; Oliovecchio E; Iorio A; Mannucci PM
Semin Thromb Hemost; 2011 Jul; 37(5):511-21. PubMed ID: 22102194
[TBL] [Abstract][Full Text] [Related]
16. Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery.
Miesbach W; Berntorp E
Eur J Haematol; 2017 Feb; 98(2):121-127. PubMed ID: 27622750
[TBL] [Abstract][Full Text] [Related]
17. New treatment approaches to von Willebrand disease.
Lavin M; O'Donnell JS
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):683-689. PubMed ID: 27913547
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of von Willebrand disease in Spain.
Batlle J; Perez-Rodriguez A; Pinto JC; Fraga EL; Rodriguez-Trillo Tch A; Fernanda Lopez-Fernandez M
Semin Thromb Hemost; 2011 Jul; 37(5):503-10. PubMed ID: 22102193
[TBL] [Abstract][Full Text] [Related]
19. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based recommendations on the treatment of von Willebrand disease in Italy.
Mannucci PM; Franchini M; Castaman G; Federici AB;
Blood Transfus; 2009 Apr; 7(2):117-26. PubMed ID: 19503633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
